ID.1
Item
histologically proven prostate cancer
boolean
C0007112 (UMLS CUI [1])
ID.2
Item
patients are hormone-naive
boolean
C0019932 (UMLS CUI [1])
ID.3
Item
patients either to begin androgen ablation therapy with lhrh agonist or already receiving therapy with lhrh agonist
boolean
C1298673 (UMLS CUI [1])
ID.4
Item
advanced prostate cancer with either positive pelvic nodes or bone/visceral metastasis
boolean
C0376358 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
ID.5
Item
must have an intact prostate (no previous surgery or xrt)
boolean
C0033572 (UMLS CUI [1,1])
C0436209 (UMLS CUI [1,2])
C0038895 (UMLS CUI [1,3])
ID.6
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
ID.7
Item
recovery from any major infection or surgical procedure
boolean
C0543467 (UMLS CUI [1,1])
C2004454 (UMLS CUI [1,2])
C3714514 (UMLS CUI [1,3])
ID.8
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
ID.9
Item
known intolerance or allergy to dutasteride
boolean
C0020517 (UMLS CUI [1,1])
C0754659 (UMLS CUI [1,2])
ID.10
Item
concomitant chemotherapy, biologic therapy, or xrt to prostate
boolean
ID.11
Item
bilateral orchiectomy
boolean
C0007347 (UMLS CUI [1])
ID.12
Item
prior malignancy within 5 years of registration
boolean
C0455471 (UMLS CUI [1])